Metaanálisis iSGLT2 en pacientes con y sin diabetes
•
0 gostou•103 visualizações
El nefrólogo Marco Vaca Gallardo comenta los resultados del estudio publicado en ASN Kidney Week 2022.
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Mais de Sociedad Española de Cardiología
Mais de Sociedad Española de Cardiología (20)
Último
Último (20)
Metaanálisis iSGLT2 en pacientes con y sin diabetes
- 1. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 2. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 3. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 4. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 5. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 6. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 7. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 8. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 9. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 10. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 11. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 12. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin
- 13. Marco Vaca Gallardo Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors Among Patients with and without Diabetes: Collaborative Meta-Analysis of Large Placebo-Controlled Presentación en Kidney week 2022: Natalie Staplin Conclusiones • En la población estudiada el tratamiento con iSGLT2 reduce el riesgo de progresión de enfermedad renal crónica y de fracaso renal agudo en pacientes con y sin diabetes mellitus. • Estos beneficios no parecen estar influenciados por la patología renal primaria. • Los beneficios absolutos superan con mucho a los potenciales riesgos.